Idexx Laboratories, Inc.

Melissa Jane Beall

Eugene Regis Krah, Iii

Ramaswamy Chandrashekar

Stacey Pazar Huth

Thomas Patrick O'Connor, Jr

Jiayou Liu

Philip R Andersen

Marilyn Strong-Townsend

Ku-chuan Hsiao

Jesse Buch

Barbara O'Brien

Phyllis Ione Tyrrell

Eugene Regis Krah

Eugene Regis

Ku-Chuan Hsiao

Barbara O'brien-Graff

Marilyn I Strong-Townsend

The invention provides canine CD20 specific antibodies, methods of making the antibodies and methods of use of the antibodies.

Canine anti-CD20 antibodies

The invention providesantigens that can be used to detectinfected animals regardless of whether the animals have been vaccinated for. The invention also provides compositions and methods for determining the presence ofantigens and antibodies.

[object Object]

antigens that can be used to differentiateinfected animals from animals that have been challenged with, e.g., vaccinated against, are disclosed. The invention also provides compositions and methods for determining the presence ofantigens and antibodies.

Isolated nucleic acid molecules having a nucleotide sequence encoding feline pancreatic lipase polypeptides, splice variants, allelic variants, and fragments thereof. Isolated feline pancreatic lipase polypeptides, splice variants, allelic variants, and fragments thereof. Host cells comprising a vector containing the polynucleotide sequences and methods for expressing the polypeptides. The generation of monoclonal antibodies that specifically binds to the feline pancreatic lipase polypeptides, and cell lines secreting the monoclonal antibodies. Methods for determining the presence or amount of feline pancreatic lipase in a biological sample. The methods include using standards or calibrators of recombinant feline pancreatic lipase to quantify the lipase in a sample. Devices and kits for performing methods for detecting feline pancreatic lipase in biological samples.

Feline pancreatic lipase

The invention provides compositions and methods for the detection ofpolynucleotides and polypeptides.

Isolated nucleic acid molecules having a nucleotide sequence encoding canine pancreatic lipase polypeptides, allelic variants and fragments thereof. Vectors and host cells containing the polynucleotide sequences and methods for expressing the polypeptides. Monoclonal antibodies that specifically binds to the canine pancreatic lipase polypeptides. Cell lines secreting the monoclonal antibodies. Methods for determining the presence or amount of canine pancreatic lipase in a biological sample. The methods include using the monoclonal antibodies to specifically bind to canine pancreatic lipase polypeptides. The method includes using standards of recombinant canine pancreatic lipase. Devices and kits for performing methods for detecting canine pancreatic lipase in biological samples.

Methods to determine the presence or amount of canine pancreatic lipase with antibodies

Antibodies that bind canine pancreatic lipase

A method and device for determining whether an animal is infected with West Nile Virus (WNV), or is either not infected or vaccinated with a WNV vaccine. The method includes contacting a biological sample from the subject with a first WNV polypeptide that is not an element of the WNV vaccine, and detecting whether antibodies in the sample bind to the WNV polypeptide. If the antibodies in the sample bind to the WNV polypeptide, it can be determined that the animal is naturally infected with WNV and if the antibodies do not bind to the polypeptide, it can be determined that the animal is either vaccinated or not infected.

Detection of West Nile virus infection and vaccination

The invention provides canine CD20 nucleotide and protein sequences. These compositions are useful in the diagnosis and treatment of, e.g., CD20+ B-cell lymphoma, immune-mediated hemolytic anemia, immune-mediated thrombocytopenia, and systemic lupus erythematosus (SLE) in canines and felines.

Growing community of inventors

Cape Elizabeth, ME, United States of America

Melissa Jane Beall